Fibroblast Growth Factor 23 Is Associated With Subclinical Cerebrovascular Damage

The Northern Manhattan Study

Clinton B Wright, Nirav H. Shah, Armando J Mendez, Janet T. DeRosa, Mitsuhiro Yoshita, Mitchell S V Elkind, Ralph L Sacco, Charles DeCarli, Tatjana Rundek, Shonni Silverberg, Chuanhui Dong, Myles Wolf

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

BACKGROUND AND PURPOSE—: Elevated fibroblast growth factor 23 (FGF23) regulates phosphate homeostasis and is linked with mortality, cardiovascular events, and stroke. However, the role of FGF23 as a risk factor for subclinical cerebrovascular damage is unclear. METHODS—: We used multivariable linear and logistic regression to evaluate associations between FGF23, continuously and by quartiles, with white matter hyperintensity volume, expressed as percent intracranial volume (%ICV), and subclinical brain infarction (SBI) in a community-based stroke-free sample. RESULTS—: There were 1170 stroke-free Northern Manhattan Study (NOMAS) participants with FGF23 levels and quantitative magnetic resonance imaging data on white matter hyperintensity volume and SBI. Participants with FGF23 levels in the top quartile (range=85–1425 RU/mL) had greater white matter hyperintensity volume (β=0.19 %ICV; 95% CI, 0.04–0.33 %ICV; P=0.01) compared with those in the lowest quartile (range=15–49 RU/mL), adjusted for demographics, vascular risk factors, and estimated glomerular filtration rate. These findings remained significant in those without evidence of chronic kidney disease (estimated glomerular filtration rate

Original languageEnglish (US)
JournalStroke
DOIs
StateAccepted/In press - Mar 8 2016

Fingerprint

Brain Infarction
Glomerular Filtration Rate
Stroke
Chronic Renal Insufficiency
Linear Models
Homeostasis
Logistic Models
Phosphates
Myocardial Infarction
Magnetic Resonance Imaging
Demography
fibroblast growth factor 23
Mortality
White Matter
vascular factor

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Clinical Neurology
  • Advanced and Specialized Nursing

Cite this

Fibroblast Growth Factor 23 Is Associated With Subclinical Cerebrovascular Damage : The Northern Manhattan Study. / Wright, Clinton B; Shah, Nirav H.; Mendez, Armando J; DeRosa, Janet T.; Yoshita, Mitsuhiro; Elkind, Mitchell S V; Sacco, Ralph L; DeCarli, Charles; Rundek, Tatjana; Silverberg, Shonni; Dong, Chuanhui; Wolf, Myles.

In: Stroke, 08.03.2016.

Research output: Contribution to journalArticle

Wright, Clinton B ; Shah, Nirav H. ; Mendez, Armando J ; DeRosa, Janet T. ; Yoshita, Mitsuhiro ; Elkind, Mitchell S V ; Sacco, Ralph L ; DeCarli, Charles ; Rundek, Tatjana ; Silverberg, Shonni ; Dong, Chuanhui ; Wolf, Myles. / Fibroblast Growth Factor 23 Is Associated With Subclinical Cerebrovascular Damage : The Northern Manhattan Study. In: Stroke. 2016.
@article{b2036f4bea774f3ea41eb767904659a3,
title = "Fibroblast Growth Factor 23 Is Associated With Subclinical Cerebrovascular Damage: The Northern Manhattan Study",
abstract = "BACKGROUND AND PURPOSE—: Elevated fibroblast growth factor 23 (FGF23) regulates phosphate homeostasis and is linked with mortality, cardiovascular events, and stroke. However, the role of FGF23 as a risk factor for subclinical cerebrovascular damage is unclear. METHODS—: We used multivariable linear and logistic regression to evaluate associations between FGF23, continuously and by quartiles, with white matter hyperintensity volume, expressed as percent intracranial volume ({\%}ICV), and subclinical brain infarction (SBI) in a community-based stroke-free sample. RESULTS—: There were 1170 stroke-free Northern Manhattan Study (NOMAS) participants with FGF23 levels and quantitative magnetic resonance imaging data on white matter hyperintensity volume and SBI. Participants with FGF23 levels in the top quartile (range=85–1425 RU/mL) had greater white matter hyperintensity volume (β=0.19 {\%}ICV; 95{\%} CI, 0.04–0.33 {\%}ICV; P=0.01) compared with those in the lowest quartile (range=15–49 RU/mL), adjusted for demographics, vascular risk factors, and estimated glomerular filtration rate. These findings remained significant in those without evidence of chronic kidney disease (estimated glomerular filtration rate",
author = "Wright, {Clinton B} and Shah, {Nirav H.} and Mendez, {Armando J} and DeRosa, {Janet T.} and Mitsuhiro Yoshita and Elkind, {Mitchell S V} and Sacco, {Ralph L} and Charles DeCarli and Tatjana Rundek and Shonni Silverberg and Chuanhui Dong and Myles Wolf",
year = "2016",
month = "3",
day = "8",
doi = "10.1161/STROKEAHA.115.012379",
language = "English (US)",
journal = "Stroke",
issn = "0039-2499",
publisher = "Lippincott Williams and Wilkins",

}

TY - JOUR

T1 - Fibroblast Growth Factor 23 Is Associated With Subclinical Cerebrovascular Damage

T2 - The Northern Manhattan Study

AU - Wright, Clinton B

AU - Shah, Nirav H.

AU - Mendez, Armando J

AU - DeRosa, Janet T.

AU - Yoshita, Mitsuhiro

AU - Elkind, Mitchell S V

AU - Sacco, Ralph L

AU - DeCarli, Charles

AU - Rundek, Tatjana

AU - Silverberg, Shonni

AU - Dong, Chuanhui

AU - Wolf, Myles

PY - 2016/3/8

Y1 - 2016/3/8

N2 - BACKGROUND AND PURPOSE—: Elevated fibroblast growth factor 23 (FGF23) regulates phosphate homeostasis and is linked with mortality, cardiovascular events, and stroke. However, the role of FGF23 as a risk factor for subclinical cerebrovascular damage is unclear. METHODS—: We used multivariable linear and logistic regression to evaluate associations between FGF23, continuously and by quartiles, with white matter hyperintensity volume, expressed as percent intracranial volume (%ICV), and subclinical brain infarction (SBI) in a community-based stroke-free sample. RESULTS—: There were 1170 stroke-free Northern Manhattan Study (NOMAS) participants with FGF23 levels and quantitative magnetic resonance imaging data on white matter hyperintensity volume and SBI. Participants with FGF23 levels in the top quartile (range=85–1425 RU/mL) had greater white matter hyperintensity volume (β=0.19 %ICV; 95% CI, 0.04–0.33 %ICV; P=0.01) compared with those in the lowest quartile (range=15–49 RU/mL), adjusted for demographics, vascular risk factors, and estimated glomerular filtration rate. These findings remained significant in those without evidence of chronic kidney disease (estimated glomerular filtration rate

AB - BACKGROUND AND PURPOSE—: Elevated fibroblast growth factor 23 (FGF23) regulates phosphate homeostasis and is linked with mortality, cardiovascular events, and stroke. However, the role of FGF23 as a risk factor for subclinical cerebrovascular damage is unclear. METHODS—: We used multivariable linear and logistic regression to evaluate associations between FGF23, continuously and by quartiles, with white matter hyperintensity volume, expressed as percent intracranial volume (%ICV), and subclinical brain infarction (SBI) in a community-based stroke-free sample. RESULTS—: There were 1170 stroke-free Northern Manhattan Study (NOMAS) participants with FGF23 levels and quantitative magnetic resonance imaging data on white matter hyperintensity volume and SBI. Participants with FGF23 levels in the top quartile (range=85–1425 RU/mL) had greater white matter hyperintensity volume (β=0.19 %ICV; 95% CI, 0.04–0.33 %ICV; P=0.01) compared with those in the lowest quartile (range=15–49 RU/mL), adjusted for demographics, vascular risk factors, and estimated glomerular filtration rate. These findings remained significant in those without evidence of chronic kidney disease (estimated glomerular filtration rate

UR - http://www.scopus.com/inward/record.url?scp=84960191962&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84960191962&partnerID=8YFLogxK

U2 - 10.1161/STROKEAHA.115.012379

DO - 10.1161/STROKEAHA.115.012379

M3 - Article

JO - Stroke

JF - Stroke

SN - 0039-2499

ER -